<DOC>
	<DOCNO>NCT02600975</DOCNO>
	<brief_summary>This clinical trial healthy volunteer administer experimental malaria vaccine , R21 . The R21 vaccine administer adjuvant AS01B . All vaccination administer intramuscularly . Each volunteer receive three vaccination total . There two different vaccine schedule : Group 1 receive R21 10µg AS01B day 0 , 28 , 56 . Group 2 receive R21 50µg AS01B day 0 , 28 , 56 . The study assess safety vaccine , immune response vaccination . Immune responses measure test blood sample . Healthy adult volunteer recruit Oxford Southampton , England .</brief_summary>
	<brief_title>A Study Assess Safety Immunogenicity Malaria Vaccine Candidate , R21 , Administered With AS01B</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<criteria>The volunteer must satisfy follow criterion eligible study : Healthy adult age 18 50 year Able willing ( Investigator 's opinion ) comply study requirement Willing allow investigator discuss volunteer 's medical history General Practitioner For female , willingness practice continuous effective contraception ( see ) study negative pregnancy test day ( ) screen vaccination Agreement refrain blood donation course study Provide write informed consent The volunteer may enter study follow apply : Participation another research study involve receipt investigational product 30 day precede enrolment , plan use study period Prior receipt investigational malaria vaccine investigational vaccine likely impact interpretation trial data . Administration immunoglobulins and/or blood product within three month precede plan administration vaccine candidate Any confirm suspected immunosuppressive immunodeficient state , include HIV infection ; asplenia ; recurrent , severe infection chronic ( 14 day ) immunosuppressant medication within past 6 month ( inhaled topical steroid allow ) History allergic disease reaction likely exacerbate component vaccine Any history anaphylaxis relation vaccination Pregnancy , lactation willingness/intention become pregnant study History cancer ( except basal cell carcinoma skin cervical carcinoma situ ) History serious psychiatric condition likely affect participation study Any serious chronic illness require hospital specialist supervision Suspected known current alcohol abuse define alcohol intake great 42 unit every week Suspected known inject drug abuse 5 year precede enrolment Seropositive hepatitis B surface antigen ( HBsAg ) Seropositive hepatitis C virus ( antibody HCV ) History clinical malaria ( specie ) Travel malaria endemic region study period within previous six month Any clinically significant abnormal find screen biochemistry haematology blood test urinalysis Any significant disease , disorder finding may significantly increase risk volunteer participation study , affect ability volunteer participate study impair interpretation study data Inability study team contact volunteer 's GP confirm medical history safety participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>